From Wikipedia, the free encyclopedia
Content deleted Content added
| Line 23: | Line 23: | ||
|
In 2005, David co-founded Kythera Biopharmaceuticals (NASDAQ: KYTH), where he served as Chief Science Officer. The company developed [https://www.mykybella.com/ Kybella], the first FDA-approved injectable drug for reducing submental fat.<ref>{{Cite press release|date=April 29, 2015|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm444978.htm|title=FDA approves treatment for fat below the chin|publisher=U.S. Food and Drug Administration|language=en|access-date=2016-03-09|url-status=dead|archive-url=https://web.archive.org/web/20150501175027/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm444978.htm|archive-date=2015-05-01}}</ref> Kythera went public in 2012 and was acquired by Allergan in 2015 for $2.1 billion.<ref>{{Cite web|url=https://www.bloomberg.com/news/articles/2015-06-17/allergan-to-buy-kythera-biopharmaceuticals-for-2-1-billion|title=Allergan to Buy Kythera Biopharmaceuticals for $2.1 Billion|last=Sachetta|first=Ryan|website=Bloomberg.com|access-date=2016-03-09}}</ref><ref>{{Cite web|url=http://www.fiercebiotech.com/special-reports/top-10-biotech-ipos-2012|title=Top 10 biotech IPOs of 2012|website=FierceBiotech|access-date=2016-03-09}}</ref> |
In 2005, David co-founded Kythera Biopharmaceuticals (NASDAQ: KYTH), where he served as Chief Science Officer. The company developed [https://www.mykybella.com/ Kybella], the first FDA-approved injectable drug for reducing submental fat.<ref>{{Cite press release|date=April 29, 2015|url=https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm444978.htm|title=FDA approves treatment for fat below the chin|publisher=U.S. Food and Drug Administration|language=en|access-date=2016-03-09|url-status=dead|archive-url=https://web.archive.org/web/20150501175027/https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm444978.htm|archive-date=2015-05-01}}</ref> Kythera went public in 2012 and was acquired by Allergan in 2015 for $2.1 billion.<ref>{{Cite web|url=https://www.bloomberg.com/news/articles/2015-06-17/allergan-to-buy-kythera-biopharmaceuticals-for-2-1-billion|title=Allergan to Buy Kythera Biopharmaceuticals for $2.1 Billion|last=Sachetta|first=Ryan|website=Bloomberg.com|access-date=2016-03-09}}</ref><ref>{{Cite web|url=http://www.fiercebiotech.com/special-reports/top-10-biotech-ipos-2012|title=Top 10 biotech IPOs of 2012|website=FierceBiotech|access-date=2016-03-09}}</ref> |
||
|
In 2011, he also co-founded [ |
In 2011, he also co-founded [ Biotechnology].<ref>{{Cite web|url=http://www.fiercebiotech.com/story/backed-lineup-marquee-vcs-biotech-startup-tackles-hard-science-aging/2016-02-03|title=Backed by a lineup of marquee VCs, Unity Biotechnology tackles the hard science of aging|website=FierceBiotech|access-date=2016-03-09}}</ref><ref name=”SEC S-1″>{{cite web|url=https://www.sec.gov/Archives/edgar/data/1463361/000119312518108850/d535851ds1.htm |title=Unity SEC S-1 Form|date=April 5, 2018|via=sec.gov|access-date=2018-11-14}}</ref><ref>{{Cite web|url=http://fortune.com/2016/02/03/mayo-unity-biotechnology-anti-aging/|title=Mayo Clinic Taps Silicon Valley to Help People Age Gracefully|website=Fortune|access-date=2016-03-09}}</ref><ref>{{Cite web|url=https://www.theatlantic.com/science/archive/2016/02/clearing-retired-cells-extends-life/459723/|title=Clearing the Body’s Retired Cells Slows Aging and Extends Life|last=Yong|first=Ed|website=The Atlantic|date=3 February 2016|language=en-US|access-date=2016-03-09}}</ref><ref>{{Cite web|url=https://www.npr.org/sections/health-shots/2016/02/03/465354874/boosting-lifespan-by-clearing-out-cellular-clutter|title=Boosting Life Span By Clearing Out Cellular Clutter|website=NPR.org|access-date=2016-03-09}}</ref> |
||
|
=== Recent Work === |
=== Recent Work === |
||
Revision as of 17:13, 1 December 2025
American scientist and entrepreneur
|
Nathaniel David |
|
|---|---|
 |
|
| Born |
San Francisco, California, U.S.
|
| Alma mater | Harvard University, University of California, Berkeley |
| Known for | Kythera Biopharmaceuticals, Kybella, Jupiter Bioventures |
| Awards | MIT Technology Review Young Innovators Under 35 |
| Scientific career | |
| Fields | Biotechnology |
| Institutions | Kythera Biopharmaceuticals, Unity Biotechnology, Jupiter Bioventures |
Nathaniel David is an American scientist and biotechnology entrepreneur who has co-founded several life sciences companies that together have raised more than $1.5 billion in financing and contributed to the development of multiple FDA-approved medicines, including alogliptin, trelagliptin, gemigliptin, plazomicin, and deoxycholic acid.
Biography
Education and Career
David earned an A.B. in Biology from Harvard University and a Ph.D. in Molecular and Cellular Biology from University of California, Berkeley.[1] While completing his doctorate, he co-founded Syrrx in 1999. The company developed a high-throughput structural biology platform that used automation and miniaturization to accelerate protein structure determination.[2][3] David was named to the MIT’s list of Innovators Under 35, a list of top global innovators under the age of 35. Syrrx was acquired by Takeda Pharmaceutical Company in 2005, and its research contributed to the development of Nesina (alogliptin), a diabetes drug approved by the FDA.[4][5]
David later co-founded Achaogen (NASDAQ: AKAO), focused on developing treatments for antibiotic-resistant infections. Achaogen developed Zemdri (plazomicin), which was approved by the FDA for complicated urinary tract infections.
In 2005, David co-founded Kythera Biopharmaceuticals (NASDAQ: KYTH), where he served as Chief Science Officer. The company developed Kybella, the first FDA-approved injectable drug for reducing submental fat.[6] Kythera went public in 2012 and was acquired by Allergan in 2015 for $2.1 billion.[7][8]
In 2011, he also co-founded Unity Biotechnology.[9][10][11][12][13]
Recent Work
In 2021, David co-founded Jupiter Bioventures with former National Cancer Institute director Ned Sharpless. Jupiter Bioventures is a venture foundry that supports the development of therapeutic companies based on emerging biological science. It launched with an initial fund of $70 million and focuses on areas such as oncology and immunology.
References
- ^ “Biotech on brink of breakthroughs”. SFGate. 22 February 2004. Retrieved 2016-03-09.
- ^ Pollack, Andrew (2000-07-04). “Analyzing Proteins With X-Rays, Crystals and Some Luck”. The New York Times. ISSN 0362-4331. Retrieved 2016-03-09.
- ^ Pollack, Andrew (2000-07-04). “The Next Chapter in the Book of Life Is Written in the Proteins”. The New York Times. ISSN 0362-4331. Retrieved 2016-03-09.
- ^ Pollack, Andrew (2005-04-20). “Some in Biotech Prefer an Acquisition to an I.P.O.” The New York Times. ISSN 0362-4331. Retrieved 2016-03-09.
- ^ Parsa, Kishore Vl; Pal, Manojit (2011-08-01). “Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview”. Expert Opinion on Drug Discovery. 6 (8): 855–869. doi:10.1517/17460441.2011.588695. ISSN 1746-045X. PMID 22651127. S2CID 24271265.
- ^ “FDA approves treatment for fat below the chin” (Press release). U.S. Food and Drug Administration. April 29, 2015. Archived from the original on 2015-05-01. Retrieved 2016-03-09.
- ^ Sachetta, Ryan. “Allergan to Buy Kythera Biopharmaceuticals for $2.1 Billion”. Bloomberg.com. Retrieved 2016-03-09.
- ^ “Top 10 biotech IPOs of 2012”. FierceBiotech. Retrieved 2016-03-09.
- ^ “Backed by a lineup of marquee VCs, Unity Biotechnology tackles the hard science of aging”. FierceBiotech. Retrieved 2016-03-09.
- ^ “Unity SEC S-1 Form”. April 5, 2018. Retrieved 2018-11-14 – via sec.gov.
- ^ “Mayo Clinic Taps Silicon Valley to Help People Age Gracefully”. Fortune. Retrieved 2016-03-09.
- ^ Yong, Ed (3 February 2016). “Clearing the Body’s Retired Cells Slows Aging and Extends Life”. The Atlantic. Retrieved 2016-03-09.
- ^ “Boosting Life Span By Clearing Out Cellular Clutter”. NPR.org. Retrieved 2016-03-09.
